Public-market balance sheet screen

listed life-science balance sheets. One screen.

Search the screening universe by ticker or company, then sort the capital structure that matters: cash, debt, enterprise value and diluted share count.

Subscribe on Substack Snapshot: Sep 22, 2026
Prices update daily
Full rebuild weekly

listed companies

cash figures in snapshot

share counts in snapshot

Prices: Sep 18, 2026 close · Financials: latest SEC filings · Fully Diluted source site

Readout Radar

124 trial readouts expected in the next 90 days

Full catalyst calendar

Now - Sep 22, 2026 AAPG Olverembatinib 20mg Phase 1
Now - Sep 22, 2026 APMD Aroxybutynin and Atomoxetine Phase 3
Now - Sep 22, 2026 ZBIO Obexelimab Phase 3
Now - Sep 23, 2026 CLYM CLYM116 Phase 1
Now - Sep 23, 2026 DWTX Halneuron Phase 2
Now - Sep 23, 2026 ELVN ELVN-002 Phase 1
Now - Sep 23, 2026 GLUE MRT-8102 Phase 1
Now - Sep 23, 2026 STTK SL-325 Phase 1

Daily tape

Daily movers

Five leaders and five laggards from the biopharma screen.

Full Daily Movers →

No companies match.Adjust the screener or clear all filters.

MethodologyPrices from market data; cash, debt and shares from latest SEC filings. Debt is set to zero only where filings disclose no debt; EV and net cash stay blank when an input is unavailable. “Shares Out” uses basic shares outstanding where available, otherwise the stated basis. True FDSO adds disclosed options, RSUs, warrants and convertible securities to basic shares; each FDSO cell carries its coverage basis. “Mkt Cap × Cash” is market cap divided by cash; it is blank when cash is zero, negative, or unavailable. “FDMC × Net Cash” is FD market cap divided by net cash; it is blank when net cash is zero or an input is unavailable.

Readout Calendar

Exact-date ClinicalTrials.gov primary-completion entries only. Estimated reporting windows are directional and do not represent company guidance.

Primary completion + 6 to 12 weeks

Material Events

Full feed →